With $11.6m that has been raised in recent times, why the urgency to secure another tranche at this time?
My hope is that the funds are 'available' to draw-down if required rather than having to pay interest on the funds while it sits in our account.
The dose level 2 participants have all had their manufacturing run completed and the two CORE-NK trials are 90% funded by the MDA and Case Western so there is little funding required there. So why the urgency?
Speaking of Case Western. The Principle Investigator in that trial has left the program. Dr. J Eva Selfridge ceased her employment in February this year. The new Principle Investigator is Dr. Benjamin Tomlinson.
During the investor webinar, RMQ told us that she was going to visit the principle investigator during her visit to the USA.
The market needed to be updated with the change in P.I. as well as the outcome of the meeting. You cannot tell me that during their in-person discussions RMQ would not be provided with an update on the status of the four patients.
CHM Price at posting:
0.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)